The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.

Omeros' stock is volatile, driven by the potential FDA approval of narsoplimab for HSCT-TMA, despite past setbacks including ...

Teos Therapeutics (ITOS) announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor ...

The following is a summary of “Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a ...

DBV Technologies (DBVT) stock shot up 29% in post-market after the company said it has aligned with the FDA on an accelerated approval pathway for its peanut allergy patch Viaskin.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.

A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...

The new FDA guidance outlines how surrogate or intermediate clinical endpoints can support accelerated approval.